A recent ₦21 billion rights issue from a leading domestic manufacturer has sent a clear and powerful signal across the continent's investment landscape, suggesting a profound transformation is underway within Nigeria's pharmaceutical sector. This move is more than just a successful capital raise;
The Race for a New Generation of Medicines The biopharmaceutical landscape is in the midst of a revolution, driven by the unprecedented potential of gene therapies and mRNA vaccines. These advanced therapies promise to treat, and even cure, diseases once considered intractable. However, their
In the high-stakes world of biochemical and metabolic research, the integrity of an entire study can often hinge on the quality and consistency of a single, seemingly simple reagent. For years, scientists have navigated a complex and frequently opaque global supply chain for critical compounds like
A New Era of Onshoring: Lillys Multi-Billion-Dollar Manufacturing Pivot In a striking departure from decades of industry practice, pharmaceutical giant Eli Lilly is executing a profoundly confident and expensive strategic realignment by committing over $50 billion over the past five years to expand
The journey from a promising chemical compound to a life-saving medicine on a pharmacy shelf is notoriously long, arduous, and astronomically expensive, often representing a decade-long gamble with billions of dollars at stake. This traditional "artisanal" approach to chemistry, reliant on manual
Picture a world where a single treatment could cure a life-threatening disease by rewriting the very code of a patient’s biology. Cell and gene therapies (CGT) are making this vision a reality, offering personalized solutions that repair or replace faulty cells and genetic material. These therapies
